CA1214727A - Composes injectable contenant du 1-(2-hydroxyethyl) -5-nitro imidazole - Google Patents

Composes injectable contenant du 1-(2-hydroxyethyl) -5-nitro imidazole

Info

Publication number: CA1214727A
Authority: CA; Canada
Prior art keywords: particles; microns; metronidazole; maximum dimension; weight
Prior art date: 1983-08-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000461262A

Other languages

English (en)

Inventor

John H. Bell

Robert P. Haslam

Andrew Lewis

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

May and Baker Ltd

Original Assignee

May and Baker Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-19

Filing date

1984-08-17

Publication date

1986-12-02

1984-08-17 Application filed by May and Baker Ltd filed Critical May and Baker Ltd

1986-12-02 Application granted granted Critical

1986-12-02 Publication of CA1214727A publication Critical patent/CA1214727A/fr

Status Expired legal-status Critical Current

Links

239000007972 injectable composition Substances 0.000 title abstract description 3
239000002245 particle Substances 0.000 claims abstract description 70
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 66
229960000282 metronidazole Drugs 0.000 claims abstract description 65
230000007935 neutral effect Effects 0.000 claims abstract description 14
229940102213 injectable suspension Drugs 0.000 claims abstract 4
239000000725 suspension Substances 0.000 claims description 36
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
210000001124 body fluid Anatomy 0.000 claims description 10
239000010839 body fluid Substances 0.000 claims description 10
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
-1 sorbitan fatty acid Chemical class 0.000 claims description 9
239000007900 aqueous suspension Substances 0.000 claims description 8
239000003755 preservative agent Substances 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 7
239000000375 suspending agent Substances 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 6
230000002335 preservative effect Effects 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
239000004359 castor oil Substances 0.000 claims description 4
235000019438 castor oil Nutrition 0.000 claims description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
235000019445 benzyl alcohol Nutrition 0.000 claims description 3
238000007046 ethoxylation reaction Methods 0.000 claims description 3
239000000787 lecithin Substances 0.000 claims description 3
235000010445 lecithin Nutrition 0.000 claims description 3
229940067606 lecithin Drugs 0.000 claims description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
229940086737 allyl sucrose Drugs 0.000 claims description 2
239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
125000002843 carboxylic acid group Chemical group 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
229920006158 high molecular weight polymer Polymers 0.000 claims description 2
229920001451 polypropylene glycol Polymers 0.000 claims description 2
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000000243 solution Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
239000010419 fine particle Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000013019 agitation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
238000003801 milling Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000009736 wetting Methods 0.000 description 2
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002356 laser light scattering Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000011343 solid material Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA000461262A 1983-08-19 1984-08-17 Composes injectable contenant du 1-(2-hydroxyethyl) -5-nitro imidazole Expired CA1214727A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB838322364A GB8322364D0 (en)	1983-08-19	1983-08-19	Compositions of matter
GB8322364		1983-08-19

Publications (1)

Publication Number	Publication Date
CA1214727A true CA1214727A (fr)	1986-12-02

Family

ID=10547557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000461262A Expired CA1214727A (fr)	1983-08-19	1984-08-17	Composes injectable contenant du 1-(2-hydroxyethyl) -5-nitro imidazole

Country Status (17)

Country	Link
JP (1)	JPS6067468A (fr)
AU (1)	AU577055B2 (fr)
BE (1)	BE900381A (fr)
CA (1)	CA1214727A (fr)
CH (1)	CH662812A5 (fr)
DE (1)	DE3430354A1 (fr)
DK (1)	DK165817C (fr)
FR (1)	FR2560043B1 (fr)
GB (2)	GB8322364D0 (fr)
HU (1)	HU192990B (fr)
IL (1)	IL72714A (fr)
IT (1)	IT1213208B (fr)
LU (1)	LU85511A1 (fr)
NL (1)	NL8402510A (fr)
NZ (1)	NZ209270A (fr)
SE (1)	SE460095B (fr)
ZA (1)	ZA846431B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL194638C (nl) *	1986-12-19	2002-10-04	Novartis Ag	Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
US7849856B2 (en)	2001-06-25	2010-12-14	3M Innovative Properties Company	Respirator valve

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB213928A (en) *	1923-04-06	1925-07-02	Deutsche Werke Ag	Improvements in or relating to compensated induction motors for single or polyphase alternating current
US3457348A (en) *	1966-06-27	1969-07-22	American Cyanamid Co	Stable syringeable suspensions of parenteral drugs in complex floc form
GB1430411A (en) *	1973-04-05	1976-03-31	May & Baker Ltd	Method and compositions for combating swine dysentery
US4029782A (en) *	1975-04-28	1977-06-14	Eli Lilly And Company	Cefazolin suspension for parenteral administration
GB2000025A (en) *	1977-05-14	1979-01-04	Pfizer Ltd	Nitroimidazole formulations
DE2932691A1 (de) *	1979-08-11	1981-04-09	Bayer Ag, 5090 Leverkusen	Antimykotische mittel mit hoeherer freisetzung der wirkstoffe

1983
- 1983-08-19 GB GB838322364A patent/GB8322364D0/en active Pending
1984
- 1984-08-13 IT IT8422323A patent/IT1213208B/it active
- 1984-08-15 NL NL8402510A patent/NL8402510A/nl not_active Application Discontinuation
- 1984-08-16 FR FR8412854A patent/FR2560043B1/fr not_active Expired
- 1984-08-17 BE BE0/213510A patent/BE900381A/fr not_active IP Right Cessation
- 1984-08-17 GB GB08420959A patent/GB2145088B/en not_active Expired
- 1984-08-17 JP JP59170517A patent/JPS6067468A/ja active Pending
- 1984-08-17 LU LU85511A patent/LU85511A1/fr unknown
- 1984-08-17 SE SE8404130A patent/SE460095B/sv not_active IP Right Cessation
- 1984-08-17 IL IL72714A patent/IL72714A/xx unknown
- 1984-08-17 CH CH3960/84A patent/CH662812A5/fr not_active IP Right Cessation
- 1984-08-17 HU HU843127A patent/HU192990B/hu not_active IP Right Cessation
- 1984-08-17 AU AU32022/84A patent/AU577055B2/en not_active Ceased
- 1984-08-17 NZ NZ209270A patent/NZ209270A/en unknown
- 1984-08-17 ZA ZA846431A patent/ZA846431B/xx unknown
- 1984-08-17 DE DE19843430354 patent/DE3430354A1/de not_active Ceased
- 1984-08-17 DK DK397084A patent/DK165817C/da not_active IP Right Cessation
- 1984-08-17 CA CA000461262A patent/CA1214727A/fr not_active Expired

Also Published As

Publication number	Publication date
BE900381A (fr)	1985-02-18
HUT35650A (en)	1985-07-29
NZ209270A (en)	1988-02-29
AU577055B2 (en)	1988-09-15
SE8404130D0 (sv)	1984-08-17
IL72714A (en)	1988-09-30
FR2560043B1 (fr)	1988-08-05
DK397084A (da)	1985-02-20
SE8404130L (sv)	1985-02-20
GB2145088B (en)	1986-10-08
FR2560043A1 (fr)	1985-08-30
CH662812A5 (fr)	1987-10-30
DK165817C (da)	1993-06-21
ZA846431B (en)	1985-03-27
NL8402510A (nl)	1985-03-18
DE3430354A1 (de)	1985-03-07
IT1213208B (it)	1989-12-14
GB8322364D0 (en)	1983-09-21
GB8420959D0 (en)	1984-09-19
JPS6067468A (ja)	1985-04-17
DK397084D0 (da)	1984-08-17
LU85511A1 (fr)	1985-04-24
HU192990B (en)	1987-08-28
DK165817B (da)	1993-01-25
IT8422323A0 (it)	1984-08-13
SE460095B (sv)	1989-09-11
AU3202284A (en)	1985-02-21
GB2145088A (en)	1985-03-20

Legal Events

Date	Code	Title	Description
2004-08-17	MKEX	Expiry

Publication	Publication Date	Title
RU2260429C2 (ru)	2005-09-20	Составы моксифлоксацина, содержащие поваренную соль
CN101835473B (zh)	2012-12-05	一种含有拉坦前列腺素的眼药组合物
JP2024045290A (ja)	2024-04-02	ベンダムスチンの製剤
JPH06501258A (ja)	1994-02-10	非水性のパーフルオロ化担体中に懸濁したドラッグデリバリー賦形剤
US9456980B2 (en)	2016-10-04	Latanoprost-containing aqueous pharmaceutical composition
TWI495469B (zh)	2015-08-11	含有氟喹諾酮抗生素藥物之經改良藥學組成物
GB2359747A (en)	2001-09-05	An anaesthetic formulation comprising micelles and propofol
GB2147263A (en)	1985-05-09	Compositions for making vesicles
CN108883064B (zh)	2022-09-16	包含pvp-i的眼用组合物
DE60215129T2 (de)	2007-02-15	Esmolol-enthaltende zubereitungen
RU2257892C2 (ru)	2005-08-10	Прозрачные стабильные композиции пропофола
GB2151203A (en)	1985-07-17	Compositions for making vesicles
CA1249223A (fr)	1989-01-24	Formulations de medicaments solides et suspensions stables
JP2939082B2 (ja)	1999-08-25	安定なビタミンａパルミテート及びビタミンｅ類可溶化点眼剤
US4038389A (en)	1977-07-26	Medroxyprogesterone acetate compositions
ITMI20011389A1 (it)	2002-12-29	Formulazioni farmaceutiche acquose di cromoglicato sodico
US5696172A (en)	1997-12-09	Injectable mesna solutions
US4289783A (en)	1981-09-15	Etomidate-containing compositions
GB2145088A (en)	1985-03-20	Metronidazole injectable compositions
WO2019107569A1 (fr)	2019-06-06	Produit ophtalmique
CA2022513A1 (fr)	1991-02-03	Compose de phenytoine sodium pour administration intraveineuse
UA129938C2 (uk)	2025-09-17	Офтальмологічні композиції, що містять комбінацію бринзоламіду та бримонідину
CA2875351C (fr)	2021-08-31	Formulations antibiotiques injectables et leurs procedes d'utilisation
WO1988009665A1 (fr)	1988-12-15	Pommades ophtalmiques sans conservateurs
DE102004006048B4 (de)	2009-11-26	Intravenös zu verabreichende Injektions-oder Infusionslösung enthaltend ein Kombinationsarzneimittel zur Verwendung als konstrastverstärkendes Mittel in der MR Angiographie